The Investor Manifesto
Advertisement
  • Business
  • Politics
  • Investing
  • Stocks
No Result
View All Result
  • Business
  • Politics
  • Investing
  • Stocks
No Result
View All Result
The Investor Manifesto
No Result
View All Result
Home Business

Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers

June 29, 2024
in Business
Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

The Biden administration on Wednesday said it will impose inflation penalties on 64 prescription drugs for the third quarter of this year, lowering costs for certain older Americans enrolled in Medicare. 

President Joe Biden has made lowering U.S. drug prices a key pillar of his health-care agenda and reelection platform for 2024. A provision of Biden’s Inflation Reduction Act requires drugmakers to pay rebates to Medicare, the federal health program for Americans over age 65, if they hike the price of a medication faster than the rate of inflation. 

It is separate from another provision under the law that allows Medicare to negotiate lower prescription drug prices with manufacturers. On average, Americans pay two to three times more than patients in other developed nations for prescription drugs, according to the Biden administration.

Some patients will pay a lower coinsurance rate for the 64 drugs covered under Wednesday’s announcement, which fall under Medicare Part B, for the period from July 1 to Sept. 30 “since each drug company raised prices faster than the rate of inflation,” according to a release from the administration.

Some Medicare Part B patients may save as much as $4,593 per day if they use those drugs during the quarter, the release added.  

More than 750,000 Medicare patients use the drugs each year, according to the release. The medications treat conditions such as cancer, certain infections and a bone disease called osteoporosis.

“Without the Inflation Reduction Act, seniors were completely exposed to Big Pharma’s price hikes. Not anymore,” Neera Tanden, White House domestic policy advisor, said in the release.

The Centers for Medicare & Medicaid Services plans to send the first invoices to drugmakers in 2025 for the rebates owed to the program.

In December, Biden released a list of 48 prescription drugs that would be subject to inflation penalties during the first quarter of 2024.

This post appeared first on NBC NEWS

Previous Post

Walgreens plans store closures as CEO says consumers ‘stunned’ by prices

Next Post

YouTube is dominating the living room, forcing media companies to decide whether it’s friend or foe

Next Post
YouTube is dominating the living room, forcing media companies to decide whether it’s friend or foe

YouTube is dominating the living room, forcing media companies to decide whether it’s friend or foe

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent News

    Iran talks with Europeans set for Friday; White House sees ‘substantial chance’ for renewed negotiations

    Iran talks with Europeans set for Friday; White House sees ‘substantial chance’ for renewed negotiations

    June 20, 2025
    Trump’s unpredictable Middle East moves actually follow a brilliant master plan

    Trump’s unpredictable Middle East moves actually follow a brilliant master plan

    June 20, 2025
    Mali Court Seizes Control of Barrick Gold Mine Amid Escalating Dispute

    Mali Court Seizes Control of Barrick Gold Mine Amid Escalating Dispute

    June 20, 2025
    Galan Lithium Limited: A$20 million Placement to Strategic Partner

    Galan Lithium Limited: A$20 million Placement to Strategic Partner

    June 20, 2025
    Disclaimer: TheInvestorManifesto.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Popular

    Cartier Signs Agreement with Exploits Discovery To Option 100% of the Benoist, Fenton and Wilson Properties
    Investing

    Cartier Signs Agreement with Exploits Discovery To Option 100% of the Benoist, Fenton and Wilson Properties

    June 3, 2025

    Read more

    Recent News

    Iran talks with Europeans set for Friday; White House sees ‘substantial chance’ for renewed negotiations

    Iran talks with Europeans set for Friday; White House sees ‘substantial chance’ for renewed negotiations

    June 20, 2025
    Trump’s unpredictable Middle East moves actually follow a brilliant master plan

    Trump’s unpredictable Middle East moves actually follow a brilliant master plan

    June 20, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Copyright © 2025 theinvestormanifesto.com | All Rights Reserved

    No Result
    View All Result
    • Business
    • Politics
    • Investing
    • Stocks

    Copyright © 2025 theinvestormanifesto.com | All Rights Reserved